Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 134

1.

Gastric cancer: Translating novels concepts into clinical practice.

Salati M, Orsi G, Smyth E, Beretta G, De Vita F, Di Bartolomeo M, Fanotto V, Lonardi S, Morano F, Pietrantonio F, Pinto C, Rimassa L, Vasile E, Vivaldi C, Zaniboni A, Ziranu P, Cascinu S.

Cancer Treat Rev. 2019 Aug 14;79:101889. doi: 10.1016/j.ctrv.2019.101889. [Epub ahead of print] Review.

PMID:
31445415
2.

Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies.

Petrelli F, Ghidini M, Ghidini A, Perego G, Cabiddu M, Khakoo S, Oggionni E, Abeni C, Hahne JC, Tomasello G, Zaniboni A.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1174. doi: 10.3390/cancers11081174.

3.

[The toxicity profile of TAS-102. Practical considerations about neutropenia.]

Zaniboni A.

Recenti Prog Med. 2019 Jul-Aug;110(7):325-329. doi: 10.1701/3197.31743. Italian.

PMID:
31379366
4.

Yoga protocol for cancer patients: A systematic exploration of psychophysiological benefits.

Mirandola M, Sabogal Rueda MD, Andreis F, Meriggi F, Codignola C, Gadaldi E, Prochilo T, Libertini M, Di Biasi B, Abeni C, Noventa S, Rota L, Ogliosi C, Zaniboni A.

Rev Recent Clin Trials. 2019 Jul 29. doi: 10.2174/1574887114666190729143742. [Epub ahead of print]

PMID:
31362680
5.

Diagnosis of Mixed Adenoneuroendocrine Carcinoma (MANEC) after Neoadjuvant Chemotherapy for Pancreatic and Gastric Adenocarcinoma: Two Case Reports and a Review of the Literature.

Oneda E, Liserre B, Bianchi D, Rota L, Savelli G, Zorzi F, Zaniboni A.

Case Rep Oncol. 2019 Jun 13;12(2):434-442. doi: 10.1159/000501200. eCollection 2019 May-Aug.

6.

18F-Fluorocholine Uptake by a Head and Neck Meningeal Inflammatory Pseudotumor.

Savelli G, Morassi M, Cobelli M, Stefanelli A, Zaniboni A.

Clin Nucl Med. 2019 Aug;44(8):657-659. doi: 10.1097/RLU.0000000000002635.

PMID:
31274616
7.

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.

Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smiroldo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F.

JAMA Oncol. 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1467. [Epub ahead of print]

8.

18F-Fluorocholine Uptake by a Head and Neck Meningeal Inflammatory Pseudotumor.

Savelli G, Morassi M, Cobelli M, Stefanelli A, Zaniboni A.

Clin Nucl Med. 2019 Jun 1. doi: 10.1097/RLU.0000000000002635. [Epub ahead of print]

PMID:
31162252
9.

Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review.

Usmani S, Orevi M, Stefanelli A, Zaniboni A, Gofrit ON, Bnà C, Illuminati S, Lojacono G, Noventa S, Savelli G.

Crit Rev Oncol Hematol. 2019 Jun;138:29-37. doi: 10.1016/j.critrevonc.2019.03.005. Epub 2019 Mar 30. Review.

PMID:
31092382
10.

Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis.

Petrelli F, Zaniboni A, Ghidini A, Ghidini M, Turati L, Pizzo C, Ratti M, Libertini M, Tomasello G.

Cancers (Basel). 2019 Apr 17;11(4). pii: E550. doi: 10.3390/cancers11040550. Review.

11.

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F.

BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

12.

Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.

Rimassa L, Bozzarelli S, Pietrantonio F, Cordio S, Lonardi S, Toppo L, Zaniboni A, Bordonaro R, Di Bartolomeo M, Tomasello G, Dadduzio V, Tronconi MC, Piombo C, Giordano L, Gloghini A, Di Tommaso L, Santoro A.

Clin Colorectal Cancer. 2019 Jun;18(2):125-132.e2. doi: 10.1016/j.clcc.2019.02.004. Epub 2019 Feb 14.

PMID:
30846365
13.

Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.

Vernieri C, Galli F, Ferrari L, Marchetti P, Lonardi S, Maiello E, Iaffaioli RV, Zampino MG, Zaniboni A, De Placido S, Banzi M, Damiani A, Ferrari D, Rosati G, Labianca RF, Bidoli P, Frassineti GL, Nicolini M, Pavesi L, Tronconi MC, Buonadonna A, Ferrario S, Re GL, Adamo V, Tamburini E, Clerico M, Giordani P, Leonardi F, Barni S, Ciarlo A, Cavanna L, Gori S, Cinieri S, Faedi M, Aglietta M, Antista M, Dotti KF, Galli F, Di Bartolomeo M; TOSCA (Three or Six Colon Adjuvant) Investigators.

Oncologist. 2019 Mar;24(3):385-393. doi: 10.1634/theoncologist.2018-0442. Epub 2019 Jan 3.

PMID:
30606884
14.

Hair Loss Prevention by a Scalp Cooling Device in Early Breast Cancer Patients: The Poliambulanza Preliminary Experience.

Prochilo T, Huscher A, Andreis F, Mirandola M, Zaina E, Pomentale B, Pedrali C, Zanotti L, Mutti S, Zaniboni A.

Rev Recent Clin Trials. 2019;14(1):66-71. doi: 10.2174/1574887113666181120111104.

PMID:
30457055
15.

Re: Clinical and molecular features of treatment-related neuroendocrine prostate cancer.

Savelli G, Zaniboni A, Stefanelli A.

Int J Urol. 2019 Jan;26(1):142. doi: 10.1111/iju.13832. Epub 2018 Oct 24. No abstract available.

PMID:
30353954
16.

One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.

Inno A, Barni S, Ghidini A, Zaniboni A, Petrelli F.

Breast Cancer Res Treat. 2019 Jan;173(2):247-254. doi: 10.1007/s10549-018-5001-x. Epub 2018 Oct 13.

PMID:
30317424
17.

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF, Barone C, Ychou M, Peeters M, Brenner B, Hofheinz RD, Maiello E, André T, Spallanzani A, Garcia-Carbonero R, Arriaga YE, Verma U, Grothey A, Kappeler C, Miriyala A, Kalmus J, Falcone A, Zaniboni A.

Oncologist. 2019 Feb;24(2):185-192. doi: 10.1634/theoncologist.2018-0072. Epub 2018 Sep 6.

PMID:
30190299
18.

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.

Borelli B, Moretto R, Lonardi S, Bonetti A, Antoniotti C, Pietrantonio F, Masi G, Burgio V, Marmorino F, Salvatore L, Rossini D, Zaniboni A, Zucchelli G, Martignetti A, Di Battista M, Pella N, Passardi A, Boccaccino A, Leone F, Colombo C, Granetto C, Vannini F, Marsico VA, Martinelli E, Antonuzzo L, Vitello S, Delliponti L, Boni L, Cremolini C, Falcone A.

ESMO Open. 2018 Jul 9;3(4):e000403. doi: 10.1136/esmoopen-2018-000403. eCollection 2018.

19.

Integrated Diagnostic Model That Incorporates Epstein-Barr Virus DNA, Imaging, and Nasal Endoscopy to Stratify Primary Tumor and Lymph Nodes in a Patient with N1 Nasopharyngeal Carcinoma: Multidisciplinary Management.

Gamba P, Rota L, Abeni C, Huscher A, Saldi G, Soregaroli A, Padolecchia E, Zorzi F, Bignardi M, Zaniboni A.

Case Rep Oncol. 2018 May 17;11(2):289-297. doi: 10.1159/000489086. eCollection 2018 May-Aug.

20.

Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice?

Formica V, Zaniboni A, Loupakis F, Roselli M.

Int J Cancer. 2018 Nov 15;143(10):2342-2350. doi: 10.1002/ijc.31616. Epub 2018 Aug 11. Review.

PMID:
29873066

Supplemental Content

Loading ...
Support Center